Altimmune, Inc. 8-K

What Happened

• Altimmune, Inc. announced that on April 22, 2026 it entered an underwriting agreement with Leerink Partners LLC and Barclays Capital Inc.; the offering closed April 24, 2026. The company sold 64,250,000 shares of common stock (with accompanying common stock warrants) and issued up to 10,750,000 pre-funded warrants (with accompanying common stock warrants) at $3.00 per share and $2.999 per pre-funded warrant. Net proceeds are expected to be approximately $211.2 million after underwriting discounts, commissions and estimated expenses. The company plans to use the funds to advance pemvidutide clinical development (including preparation for a global pivotal Phase 3 trial in MASH), start pre-commercial activities for the program, and for general corporate purposes.

Key Details

• Offering size and pricing: 64,250,000 common shares at $3.00/share; up to 10,750,000 pre-funded warrants at $2.999 each.
• Net proceeds: ~ $211.2 million after fees and expenses.
• Warrants: Each common-stock warrant exercisable for one share at $3.00; generally exercisable immediately and expires on the earlier of (i) 5 years after issuance or (ii) 45 days after a public announcement of a successful Phase 3 readout for pemvidutide in MASH. Pre-funded warrants (exercise price $0.001) do not expire.
• Ownership limits: Common-stock warrants include a Beneficial Ownership Limitation selectable by the holder (initially 4.99% or 9.99%, up to 19.99% with notice and a 61-day delay); pre-funded warrants have a 9.99% limit (also up to 19.99% with notice and delay).
• Underwriting reps and legal: Leerink and Barclays served as representatives; Goodwin Procter LLP delivered a legal opinion.

Why It Matters

• The offering supplies Altimmune with a material cash infusion (~$211M net) to fund its lead program pemvidutide and prepare for a pivotal Phase 3 MASH trial—key near-term uses cited by management.
• The transaction issues a large number of shares plus long-dated warrants and pre-funded warrants, which will increase potential dilution if and when those instruments are exercised; investors should factor this into per-share value and share-count assumptions.
• Warrant terms (exercise price of $3.00, limited listing intention, and ownership caps) and the special 45-day post-success readout expiration condition for common warrants are important mechanics that affect potential future dilution timing and holder behavior.